Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Price Zscore is at a recent 2 week high. A recent high ZScore means price movement is accelerating at a record speed.
| MarketCap | 380M |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| P/B | 12.3 |
| P/S (ttm) | 46.6 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 10% |
| Held by Institutions % | 64% |
| 1 Day Vol Adjusted Return | 0.6 |
| 1 Month Vol Adjusted Return | 2.6 |
| 3 Month Vol Adjusted Return | 5.5 |
| 6 Month Vol Adjusted Return | -1.9 |
| 20 Days SMA Price ZScore | 2.6 |
| 50 Days SMA Price ZScore | 1.9 |
| 12 -26 Days PPO | 4.1 |
| 1 Month Average Short Volume Ratio | 40.5 |
| 1 Day Volume Change ZScore | 0.4 |
| 1 Month Daily Vol | 3.6 |
Stock news
BEDFORD, Mass., July 25, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 30, 2022 financial results after the close on Monday, August 8, 2022. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and
If you want to know who really controls Ocular Therapeutix, Inc. ( NASDAQ:OCUL ), then you'll have to look at the...
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
BEDFORD, Mass., June 08, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced senior leadership changes to strengthen the Company’s alignment around the development of its late-stage ophthalmology product portfolio. The realignment was affected to enhance Ocular’s ability to execute its strategy of building a comprehensive portfolio of asse
BEDFORD, Mass., June 01, 2022--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 8:00 AM ET at the Marriott Marquis in New York, NY.
Market forces rained on the parade of Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) shareholders today, when the analysts...
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BEDFORD, Mass., May 09, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter ended March 31, 2022, and provided updates on its ophthalmology pipeline.